76884
2-氨基苯甲酰胺
suitable for matrix substance for MALDI-MS, ≥99.0% (HPLC)
别名:
2-AB, 2-氨基苯甲酰胺, 邻氨基苯甲酰胺
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
线性分子式:
2-(H2N)C6H4CONH2
化学文摘社编号:
分子量:
136.15
UNSPSC Code:
23151817
NACRES:
NA.21
PubChem Substance ID:
EC Number:
201-851-2
Beilstein/REAXYS Number:
508509
MDL number:
Assay:
≥99% (NT), ≥99.0% (HPLC)
Form:
crystals
Quality Level
assay
≥99% (NT), ≥99.0% (HPLC)
form
crystals
technique(s)
MALDI-MS: suitable
cation traces
Ba: ≤5 mg/kg, Ca: ≤5 mg/kg, Cd: ≤5 mg/kg, Co: ≤5 mg/kg, Cr: ≤5 mg/kg, Cu: ≤5 mg/kg, Fe: ≤30 mg/kg, K: ≤50 mg/kg, Mg: ≤5 mg/kg, Mn: ≤5 mg/kg, Na: ≤150 mg/kg, Ni: ≤5 mg/kg, Pb: ≤5 mg/kg, Zn: ≤5 mg/kg
suitability
suitable for matrix substance for MALDI-MS
SMILES string
NC(=O)c1ccccc1N
InChI
1S/C7H8N2O/c8-6-4-2-1-3-5(6)7(9)10/h1-4H,8H2,(H2,9,10)
InChI key
PXBFMLJZNCDSMP-UHFFFAOYSA-N
Application
用于非选择性高效荧光标记聚糖。荧光标记灵敏度略低于邻氨基苯甲酸 (2-AA)。
Analysis Note
金属痕量分析 (ICP) 符合要求
Still not finding the right product?
Explore all of our products under 2-氨基苯甲酰胺
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
>365.0 °F
flash_point_c
> 185 °C
Yan Cai et al.
The Analyst, 138(21), 6270-6276 (2013-09-07)
Analysis of oligosaccharides by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is often limited by their low ionization efficiency and inadequate fragmentation information. Derivatizations of oligosaccharides to enhance their ionization in MS are widely used, but most of these
Nicholas T Ventham et al.
PloS one, 10(4), e0123028-e0123028 (2015-04-02)
Serum N-glycans have been identified as putative biomarkers for numerous diseases. The impact of different serum sample tubes and processing methods on N-glycan analysis has received relatively little attention. This study aimed to determine the effect of different sample tubes
Antonio da Silva et al.
Leukemia & lymphoma, 55(7), 1609-1617 (2013-09-13)
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were engineered and monitored
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| 76884-1G | 04061826165539 |